Clinical Cancer Cytogenetics

临床癌症细胞遗传学

• 批准号: 7291973
• 负责人: diane c arthur
• 金额: --
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7291973
• 关键词: Clinical; Cancer; Cytogenetics

The mission of the NCI/CCR/LP Clinical Cytogenetics Section is to provide state-of-the-art diagnostic services for patients evaluated and treated at the Mark O. Hatfield Clinical Research Center; to perform clinical translational cancer cytogenetics research; and to teach and mentor students, residents, and fellows in the principles and practices of clinical cytogenetics service and research. The goals of this project, which comprises 80 percent of the effort of the section, are to provide diagnostic service and research testing on samples from patients entered on clinical research protocols by NCI and other Institute physicians, to collaborate on NCI clinical translational research protocols, and to teach and mentor students, residents, and fellows.The Clinical Cytogenetics Section is the only intramural NIH laboratory performing cytogenetics diagnostic services. The laboratory is inspected and certified by the College of American Pathologists, the Joint Commission for Accreditation of Hospitals, and the Clinical Laboratory Improvement Act of 1988. We currently perform highly complex routine and molecular cytogenetic testing on patient samples from several institutes (NCI, NIAID, NICHD) and the Clinical Center Department of Laboratory Medicine. In greater than 80 percent of cases the testing is for acquired chromosome abnormalities in premalignant and malignant disorders, and in the remaining cases is for constitutional chromosome abnormalities. The results of our testing are used for diagnosis, classification, prognosis, and treatment planning for patients. They also provide critical information regarding the gene regions that may be important for tumor initiation and progression, and thus serve as a starting point for further molecular biologic investigations of malignant diseases.Section members are conducting routine diagnostic and research fluorescence in-situ hybridization (FISH), comparative genomic hybridization (CGH), and spectral karyotyping (SKY) analyses of patients entered on NCI clinical research protocols. Dr. Arthur is an Associate Investigator on seven active protocols as follows:a. 97-C-0178 "Fludarabine Treatment of Chronic Lymphocytic Leukemia (CLL): cDNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/ Immunotherapy Studies," PI: Wyndham Wilson, M.D., Ph.D. b. 01-C-0125 "Pilot Study of Non-myeloablative, HLA-matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies," PI: Alan S. Wayne, M.D.c. 02-C-0052 "Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes," PI: Blanche Alter, M.D. M.P.H. d. 04-C-0079 "Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas," PI: Alan S. Wayne, M.D.e. 04-C-0102 "Hematologic Malignancy Biology Study," PI: Alan S. Wayne, M.D.f. 04-C-0168 "Pediatric Phase I Trial of LMB-2 for Refractory CD25-Positive Leukemias and Lymphomas," PI: Alan S. Wayne, M.D.g. 04-C-0095 "A Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Systemic Lupus Erythematosus," PI: Steven Z. Pavletic, M.D.The cytogenetics data generated as part of these studies are clinically useful for diagnosis, classification, and treatment planning for patients. They are also important for monitoring patient response to experimental treatment, and for correlation with other research studies. They have the potential for discovery of new clinical-pathological associations among these diseases and of biological mechanisms that may be targeted with future therapies. Finally, section members teach and mentor students, residents, and fellows in the principles and practices of clinical cytogenetics service and research. In addition to mentoring three summer students and two postdoctoral fellows, Dr. Arthur is a member of the NCI/CCR/LP Resident, NCI/CCR/LP Hematopathology Fellow, and NHGRI Clinical Cytogenetics Fe

NCI/CCR/LP临床细胞遗传学部分的任务是为在Mark O. Hatfield临床研究中心评估和治疗的患者提供最新的诊断服务；进行临床转化癌细胞遗传学研究；以及教导和指导学生，居民和研究员的临床细胞遗传学服务和研究的原则和实践。该项目的目标是本节的80％的努力，是为NCI和其他研究所医生在临床研究方案中输入的患者的样本提供诊断服务和研究测试，以合作进行NCI临床转化研究协议，并教授和指导学生，居民，居民和研究员。该实验室由美国病理学家学院，医院认证联合委员会以及1988年的《临床实验室改善法》进行了检查和认证。我们目前对来自多个研究所（NCI，NIAID，NICHD，NICHD）和临床中心药物的患者样本进行了高度复杂的常规和分子细胞遗传学测试。在超过80％的病例中，该测试是针对预性疾病和恶性疾病中获得的染色体异常，其余病例则用于宪法染色体异常。我们的测试结果用于患者的诊断，分类，预后和治疗计划。他们还提供有关基因区域可能对肿瘤起始和进展很重要的关键信息，从而作为对恶性疾病的进一步分子生物学研究的起点。部分成员正在进行常规的诊断和研究荧光内效率和研究荧光实用杂交内化（FISH），比较基因组杂交（CGH）和光谱Karyoting（Sky）的研究（CHAR），并分析了Skymic karyotsing（Sky）。协议。 Arthur博士是七个主动方案的副研究人员，如下所示： 97-C-0178”慢性淋巴细胞性白血病（CLL）的氟达拉滨治疗：cDNA微阵列基因表达分析和临床前骨髓移植/免疫疗法研究，“ PI：Wyndham Wilson，M.D。 b。 01-C-0125”非毛囊，HLA匹配的同种异体干细胞移植小儿造血恶性肿瘤的试验研究，PI：Alan S. Wayne，M.D.C。 02-C-0052“遗传骨髓衰竭综合症癌症易感性的病因学研究”，PI：Blanche Alter，M.D。M.P.H. d。 04-C-0079“ BL22的儿科I期试验对于难治性CD22阳性白血病和淋巴瘤，” PI：Alan S. Wayne，M.D.E。 04-C-0102“血液系统恶性生物学研究”，PI：Alan S. Wayne，M.D.F。 04-C-0168“ LMB-2的儿科I期试验对于难治性CD25阳性白血病和淋巴瘤，” PI：Alan S. Wayne，M.D.G。 04-C-0095”一项针对严重全身性红斑狼疮的患者进行自体造血干细胞移植的试点研究，然后是史蒂芬·Z. Pavletic，M.D.Steven Z. Pavletic。它们对于监测患者对实验治疗的反应以及与其他研究的相关性也很重要。它们具有在这些疾病中发现新的临床病理相关性以及可能针对未来疗法的生物学机制的潜力。最后，部门成员在临床细胞遗传学服务和研究的原理和实践中教授和指导学生，居民和研究员。除了指导三名夏季学生和两名博士后研究员外，Arthur博士还是NCI/CCR/LP居民，NCI/CCR/LP血液病理学研究员和NHGRI Clinical Clinical Cytegenetics FE